市場調査レポート

商品コード

1679373

ドーパミン作動薬の世界市場：市場規模・シェア・動向分析 (薬剤別・投与経路別・用途別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2025年02月28日
発行: Grand View Research
ページ情報: 英文 153 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF (Single User License)

USD 5,950 857,157円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 1,001,217円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,289,337円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ドーパミン作動薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、ドーパミン作動薬の世界市場規模は2030年までに18億3,000万米ドルに達すると予測され、予測期間中にCAGR 5.70％で成長すると予測されています。

麦角アルカロイドや非麦角系ドーパミン作動薬を含む神経学的治療におけるドーパミン作動薬の需要は、医薬品分野に大きな機会を生み出しています。パーキンソン病、レストレスレッグス症候群（RLS）、高プロラクチン血症などの疾患の管理に有効であることが実証されているこれらの医薬品は、市場拡大の原動力となっています。麦角由来のドーパミン作動薬は長い間臨床で使用されてきたが、非麦角のドーパミン作動薬は安全性プロファイルと忍容性が改善されているため、好まれるようになってきています。ドーパミン作動薬の有効性を支持する臨床的エビデンスが増加するにつれ、運動障害の治療におけるドーパミン作動薬の使用は増加の一途をたどっています。

経口剤や注射剤の開発により、治療へのアクセスや患者の嗜好性はさらに広がっています。経口ドーパミン作動薬は、パーキンソン病やRLSのような慢性疾患に広く使用されており、簡便な投与と長期にわたる服薬アドヒアランスを可能にしています。一方、注射剤は、即効性と持続性が求められる急性期や進行期の治療に重要な役割を果たします。製薬会社が革新的なドラッグデリバリー方法の開発に注力していることから、市場はさらなる成長を遂げる構えです。

Teva Pharmaceutical Industries Ltd.、GSK plc.、Supernus Pharmaceuticals, Inc.、H. Lundbeck A/S、Amneal Pharmaceuticals LLC、UCB Pharma、Novartis AG、VeroScience LLC.、Pfizer Inc.、Boehringer Ingelheim Pharmaceuticals, Inc.などの製薬企業が、市場の拡大に積極的に貢献しています。これらの企業は、薬効、安全性、患者のコンプライアンスを向上させるための研究開発に取り組んでおり、これらの治療法の採用をさらに促進しています。

小売薬局は、特に慢性疾患管理に使用される経口剤のドーパミン作動薬の流通において、ますます大きな役割を果たしています。これらの薬局では、薬へのアクセスが容易なだけでなく、アドヒアランスと最適な治療結果を保証するための患者教育やカウンセリングサービスも提供しています。小売薬局は、一貫した薬の補充やサポートを提供できるため、長期的な患者ケアの重要な要素となっています。

特に治療の初期段階では、綿密なモニタリングが不可欠です。例えば、パーキンソン病患者は、外来治療に移行する前に、病院の管理下で治療を開始することがよくあります。患者が安定するにつれ、小売薬局や専門薬局は、慢性神経疾患の治療を中断することなく、継続的な投薬やサポートサービスを提供する主要な情報源となります。

ドーパミン作動薬の需要が増加し続ける中、サプライチェーン・マネジメントや医薬品流通などの課題も浮上してくる。経口剤と注射剤の両方を安定的に入手できるようにするには、強力な物流インフラと、アドヒアランスと治療成果を最大化するための患者教育に注力する必要があります。さらに、研究開発、特に新規デリバリーシステムへの継続的な投資は、製薬企業にとって、より幅広い患者集団に対応し、治療効果を高める機会となります。

ドーパミン作動薬市場：分析概要

2024年には、非麦角型ドーパミン作動薬が市場を席巻し、神経疾患の優先的治療選択肢としての地位を固めました。優れた安全性プロファイル、改善された忍容性、増加する臨床受容性により、このクラスの主要治療薬となっています。
2024年には経口剤が市場を独占しました。経口剤は、その利便性、長期にわたるアドヒアランスの利点、パーキンソン病、レストレスレッグス症候群（RLS）、高プロラクチン血症などの慢性疾患の管理における有効性により、広く好まれています。
2024年には、小売薬局が支配的な流通チャネルとして浮上しました。小売薬局が提供する利便性の向上とアクセスのしやすさにより、小売薬局はドーパミン作動薬薬を使用する患者にとって主要なアクセスポイントとなっています。
北米が市場をリードしたのは、医療インフラが整備されていること、神経疾患に対する意識が高いこと、先進的な治療選択肢があることなどが要因です。

ドーパミン作動薬の市場シェア：地域別 (2024年・2030年)
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東およびアフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

最新動向と影響分析：主な市場参入企業別
企業分類
参入企業の概要
財務実績
製品のベンチマーク
企業市場シェア分析 (2024年)
企業プロファイル
- Teva Pharmaceutical Industries Ltd
- GSK plc.
- Supernus Pharmaceuticals, Inc.
- H. Lundbeck A/S
- Amneal Pharmaceuticals LLC
- UCB Pharma
- Novartis AG
- VeroScience LLC.
- Pfizer Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.

第10章結論

図表

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 North America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 4 North America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 5 North America dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
Table 6 North America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 7 North America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 8 U.S. dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 9 U.S. dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 10 U.S. dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 11 U.S. dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Canada dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 13 Canada dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
Table 14 Canada dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 15 Canada dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Mexico dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 17 Mexico dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 18 Mexico dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 19 Mexico dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 20 Europe dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 21 Europe dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 22 Europe dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 23 Europe dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 24 Europe dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 25 UK dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 26 UK dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
Table 27 UK dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 28 UK dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 29 Germany dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 30 Germany dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 31 Germany dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 32 Germany dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 33 France dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 34 France dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 35 France dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 36 France dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Spain dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 38 Spain dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 39 Spain dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 40 Spain dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 41 Italy dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 42 Italy dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 43 Italy dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 44 Italy dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 45 Denmark dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 46 Denmark dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 47 Denmark dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 48 Denmark dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 49 Sweden dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 50 Sweden dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 51 Sweden dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 52 Sweden dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 53 Norway dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 54 Norway dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 55 Norway dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 56 Norway dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 57 Asia Pacific dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 58 Asia Pacific dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 59 Asia Pacific dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 60 Asia Pacific dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 61 Asia Pacific dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Japan dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 63 Japan dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 64 Japan dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 65 Japan dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 66 China dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 67 China dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 68 China dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 69 China dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 70 India dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 71 India dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 72 India dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 73 India dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 74 South Korea dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 75 South Korea dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 76 South Korea dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 77 South Korea dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 78 Australia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 79 Australia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 80 Australia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 81 Australia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Thailand dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 83 Thailand dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 84 Thailand dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 85 Thailand dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 86 Latin America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 87 Latin America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 88 Latin America dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 89 Latin America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 90 Latin America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Brazil dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 92 Brazil dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
Table 93 Brazil dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 94 Brazil dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 95 Argentina dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 96 Argentina dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 97 Argentina dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 98 Argentina dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 99 MEA dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 100 MEA dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 101 MEA dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 102 MEA dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 103 MEA dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 104 South Africa dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 105 South Africa dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 106 South Africa dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 107 South Africa dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 108 UAE dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 109 UAE dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 110 UAE dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 111 UAE dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
Table 116 Kuwait dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
Table 117 Kuwait dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
Table 118 Kuwait dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
Table 119 Kuwait dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Dopamine agonist market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Application segment snapshot
Fig. 10 Drug and application segment snapshot
Fig. 11 Route of administration and distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Pharmaceutical market, (USD Billion)
Fig. 14 Market dynamics
Fig. 15 Porter's five forces analysis
Fig. 16 PESTLE analysis
Fig. 17 Dopamine agonist market: Drug outlook and key takeaways
Fig. 18 Dopamine agonist market: Drug movement analysis
Fig. 19 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Non-ergot dopamine agonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Dopamine agonist market: Application outlook and key takeaways
Fig. 22 Dopamine agonist market: Application movement analysis
Fig. 23 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Restless Legs Syndrome (RLS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Hyperprolactinemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Dopamine agonist market: Route of administration outlook and key takeaways
Fig. 28 Dopamine agonist market: Route of administration movement analysis
Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Dopamine agonist market: Distribution channel outlook and key takeaways
Fig. 33 Dopamine agonist market: Distribution channel movement analysis
Fig. 34 Retail pharmacies market estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Dopamine agonist market revenue, by region, 2024 & 2030, (USD Million)
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America dopamine agonist market estimates and forecasts, 2018 - 2030 ((USD Million)
Fig. 41 Key country dynamics
Fig. 42 Target disease prevalence
Fig. 43 U.S. dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Target disease prevalence
Fig. 46 Canada dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Mexico dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Target disease prevalence
Fig. 53 UK dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Target disease prevalence
Fig. 56 Germany dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Target disease prevalence
Fig. 59 France dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Target disease prevalence
Fig. 62 Spain dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Target disease prevalence
Fig. 65 Italy dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Target disease prevalence
Fig. 68 Denmark dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Target disease prevalence
Fig. 71 Sweden dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Target disease prevalence
Fig. 74 Norway dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Rest of Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Target disease prevalence
Fig. 79 Japan dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Target disease prevalence
Fig. 82 China dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Target disease prevalence
Fig. 85 India dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Target disease prevalence
Fig. 88 Australia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 Thailand dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 South Korea dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Rest of Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Target disease prevalence
Fig. 97 Brazil dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Target disease prevalence
Fig. 100 Argentina dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 Rest of Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Target disease prevalence
Fig. 105 South Africa dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Target disease prevalence
Fig. 108 Saudi Arabia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 Target disease prevalence
Fig. 111 UAE dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Key country dynamics
Fig. 113 Target disease prevalence
Fig. 114 Kuwait dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 Rest of MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)

Product Code: GVR-4-68040-531-1

Dopamine Agonist Market Growth & Trends:

The global dopamine agonist market size is anticipated to reach USD 1.83 billion by 2030 and is projected to grow at a CAGR of 5.70% during the forecast period, according to a new report by Grand View Research, Inc. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson's disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth.

Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies.

Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care.

Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson's disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders.

As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

Dopamine Agonist Market Report Highlights:

In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.
The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia.
Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.
North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope

3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
  - 3.3.1.1. Rising prevalence of neurological disorders
  - 3.3.1.2. Growing geriatric population
  - 3.3.1.3. Advancements in drug formulations & delivery methods
- 3.3.2. Market Restraints Analysis
  - 3.3.2.1. Severe side effects & safety concerns
  - 3.3.2.2. Emerging alternative therapies
3.4. Dopamine Agonist Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape
3.5. Pipeline Analysis
- 3.5.1. Phase 1
- 3.5.2. Phase 2
- 3.5.3. Phase 3

Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis

4.1. Dopamine Agonist Market: Drug Segment Dashboard
4.2. Dopamine Agonist Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
4.3. Non-Ergot Dopamine Agonists
- 4.3.1. Non-Ergot Dopamine Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Ergot Alkaloids
- 4.4.1. Ergot Alkaloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis

5.1. Dopamine Agonist Market: Application Segment Dashboard
5.2. Dopamine Agonist Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
5.3. Parkinson's Disease
- 5.3.1. Parkinson's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Restless Legs Syndrome (RLS)
- 5.4.1. Restless Legs Syndrome (RLS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Hyperprolactinemia
- 5.5.1. Hyperprolactinemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
- 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis

6.1. Dopamine Agonist Market: Route of Administration Segment Dashboard
6.2. Dopamine Agonist Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
6.3. Oral
- 6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Injectable
- 6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis

7.1. Dopamine Agonist Market: Distribution Channel Segment Dashboard
7.2. Dopamine Agonist Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
7.3. Retail Pharmacies
- 7.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Other Pharmacies
- 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis

8.1. Dopamine Agonist Market Share, By Region, 2024 & 2030 (USD Million)
8.2. North America
- 8.2.1. North America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. Key Country Dynamics
  - 8.2.2.2. Target Disease Prevalence
  - 8.2.2.3. Regulatory Framework
  - 8.2.2.4. Reimbursement Framework
  - 8.2.2.5. U.S. Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Regulatory Framework
  - 8.2.3.4. Reimbursement Framework
  - 8.2.3.5. Canada Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Regulatory Framework
  - 8.2.4.4. Reimbursement Framework
  - 8.2.4.5. Mexico Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. Europe Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Target Disease Prevalence
  - 8.3.2.3. Regulatory Framework
  - 8.3.2.4. Reimbursement Framework
  - 8.3.2.5. Uk Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Target Disease Prevalence
  - 8.3.3.3. Regulatory Framework
  - 8.3.3.4. Reimbursement Framework
  - 8.3.3.5. Germany Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Target Disease Prevalence
  - 8.3.4.3. Regulatory Framework
  - 8.3.4.4. Reimbursement Framework
  - 8.3.4.5. France Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
  - 8.3.5.1. Key Country Dynamics
  - 8.3.5.2. Target Disease Prevalence
  - 8.3.5.3. Regulatory Framework
  - 8.3.5.4. Reimbursement Framework
  - 8.3.5.5. Italy Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
  - 8.3.6.1. Key Country Dynamics
  - 8.3.6.2. Target Disease Prevalence
  - 8.3.6.3. Regulatory Framework
  - 8.3.6.4. Reimbursement Framework
  - 8.3.6.5. Spain Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
  - 8.3.7.1. Key Country Dynamics
  - 8.3.7.2. Target Disease Prevalence
  - 8.3.7.3. Regulatory Framework
  - 8.3.7.4. Reimbursement Framework
  - 8.3.7.5. Denmark Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
  - 8.3.8.1. Key Country Dynamics
  - 8.3.8.2. Target Disease Prevalence
  - 8.3.8.3. Regulatory Framework
  - 8.3.8.4. Reimbursement Framework
  - 8.3.8.5. Sweden Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
  - 8.3.9.1. Key Country Dynamics
  - 8.3.9.2. Target Disease Prevalence
  - 8.3.9.3. Regulatory Framework
  - 8.3.9.4. Reimbursement Framework
  - 8.3.9.5. Norway Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Japan
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. China
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. India Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Target Disease Prevalence
  - 8.4.5.3. Regulatory Framework
  - 8.4.5.4. Reimbursement Framework
  - 8.4.5.5. Australia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Target Disease Prevalence
  - 8.4.6.3. Regulatory Framework
  - 8.4.6.4. Reimbursement Framework
  - 8.4.6.5. South Korea Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Target Disease Prevalence
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Reimbursement Framework
  - 8.4.7.5. Thailand Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. Latin America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. South Africa
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. South Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Saudi Arabia
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. Saudi Arabia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. UAE
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. UAE Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Kuwait Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Participant Overview
9.4. Financial Performance
9.5. Product Bench Marking
9.6. Company Market Share Analysis, 2024
9.7. Company Profiles
- 9.7.1. Teva Pharmaceutical Industries Ltd
  - 9.7.1.1. Participant's Overview
  - 9.7.1.2. Financial Performance
  - 9.7.1.3. Product Benchmarking
  - 9.7.1.4. Recent Developments/ Strategic Initiatives
- 9.7.2. GSK plc.
  - 9.7.2.1. Participant's Overview
  - 9.7.2.2. Financial Performance
  - 9.7.2.3. Product Benchmarking
  - 9.7.2.4. Recent Developments/ Strategic Initiatives
- 9.7.3. Supernus Pharmaceuticals, Inc.
  - 9.7.3.1. Participant's Overview
  - 9.7.3.2. Financial Performance
  - 9.7.3.3. Product Benchmarking
  - 9.7.3.4. Recent Developments/ Strategic Initiatives
- 9.7.4. H. Lundbeck A/S
  - 9.7.4.1. Participant's Overview
  - 9.7.4.2. Financial Performance
  - 9.7.4.3. Product Benchmarking
  - 9.7.4.4. Recent Developments/ Strategic Initiatives
- 9.7.5. Amneal Pharmaceuticals LLC
  - 9.7.5.1. Participant's Overview
  - 9.7.5.2. Financial Performance
  - 9.7.5.3. Product Benchmarking
  - 9.7.5.4. Recent Developments/ Strategic Initiatives
- 9.7.6. UCB Pharma
  - 9.7.6.1. Participant's Overview
  - 9.7.6.2. Financial Performance
  - 9.7.6.3. Product Benchmarking
  - 9.7.6.4. Recent Developments/ Strategic Initiatives
- 9.7.7. Novartis AG
  - 9.7.7.1. Participant's Overview
  - 9.7.7.2. Financial Performance
  - 9.7.7.3. Product Benchmarking
  - 9.7.7.4. Recent Developments/ Strategic Initiatives
- 9.7.8. VeroScience LLC.
  - 9.7.8.1. Participant's Overview
  - 9.7.8.2. Financial Performance
  - 9.7.8.3. Product Benchmarking
  - 9.7.8.4. Recent Developments/ Strategic Initiatives
- 9.7.9. Pfizer Inc.
  - 9.7.9.1. Participant's Overview
  - 9.7.9.2. Financial Performance
  - 9.7.9.3. Product Benchmarking
  - 9.7.9.4. Recent Developments/ Strategic Initiatives
- 9.7.10. Boehringer Ingelheim Pharmaceuticals, Inc.
  - 9.7.10.1. Participant's Overview
  - 9.7.10.2. Financial Performance
  - 9.7.10.3. Product Benchmarking
  - 9.7.10.4. Recent Developments/ Strategic Initiatives

ドーパミン作動薬の世界市場：市場規模・シェア・動向分析 (薬剤別・投与経路別・用途別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

ドーパミン作動薬市場の成長と動向：

ドーパミン作動薬市場：分析概要

目次

第1章分析方法・範囲

第2章エグゼクティブサマリー

第3章ドーパミン作動薬市場：変動要因・傾向・範囲

第4章ドーパミン作動薬市場：薬剤別の推定・動向分析

第5章ドーパミン作動薬市場：用途別の推定・動向分析

第6章ドーパミン作動薬市場：投与経路別の推定・動向分析

第7章ドーパミン作動薬市場：流通チャネル別の推定・動向分析

第8章ドーパミン作動薬市場：地域別の推定・動向分析

第9章競合情勢

第10章結論

List of Tables

List of Figures

Dopamine Agonist Market Growth & Trends:

Dopamine Agonist Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope

Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis

Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis

Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis

Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

Chapter 10. Conclusion

ドーパミン作動薬の世界市場：市場規模・シェア・動向分析 (薬剤別・投与経路別・用途別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

ドーパミン作動薬市場の成長と動向：

ドーパミン作動薬市場：分析概要

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 ドーパミン作動薬市場：変動要因・傾向・範囲

第4章 ドーパミン作動薬市場：薬剤別の推定・動向分析

第5章 ドーパミン作動薬市場：用途別の推定・動向分析

第6章 ドーパミン作動薬市場：投与経路別の推定・動向分析

第7章 ドーパミン作動薬市場：流通チャネル別の推定・動向分析

第8章 ドーパミン作動薬市場：地域別の推定・動向分析

第9章 競合情勢

第10章 結論

List of Tables

List of Figures

Dopamine Agonist Market Growth & Trends:

Dopamine Agonist Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope

Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis

Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis

Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis

Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

Chapter 10. Conclusion

第1章分析方法・範囲

第2章エグゼクティブサマリー

第3章ドーパミン作動薬市場：変動要因・傾向・範囲

第4章ドーパミン作動薬市場：薬剤別の推定・動向分析

第5章ドーパミン作動薬市場：用途別の推定・動向分析

第6章ドーパミン作動薬市場：投与経路別の推定・動向分析

第7章ドーパミン作動薬市場：流通チャネル別の推定・動向分析

第8章ドーパミン作動薬市場：地域別の推定・動向分析

第9章競合情勢

第10章結論